Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)

Recruiting now

Conditions studied: Lung Cancer (Diagnosis)

In brief

CT imaging data from lung cancer (NSCLC and SCLC) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Key facts

Study ID

NCT07059923

Run by

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

People needed

400

Starts

2025-07-01

Expected to finish

2026-08-01

Last updated by the study team

2025-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients were treated for lung cancer in Wuhan Union Hospital from July 2025 to July 2026;
• Aged > 18 years old;
• At least one CT scan before treatment;
• Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

You may not qualify if…

• Poor image quality;
• Incomplete clinical data or loss of follow-up;
• Presence of another primary malignancy other than lung cancer;
• Unclear pathological diagnosis.

Where it is running

• Union Hospital，Tongji Medical College，Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.